Castle Biosciences Inc 's

The company primarily competes against traditional clinical and pathology staging criteria with its DecisionDx-Melanoma and TissueCypher tests, which have been standard of care in the U.S. for many years. Adoption of the company's tests by clinicians and physicians may depend on their inclusion in national or clinical guideline recommendations. Current competitors in the disease space include SkylineDx. For the TissueCypher test, additional competition may arise from Interpace Diagnostics and Lucid Diagnostics, particularly in GERD screening and prognostic testing for Barrett's Esophagus. In 2025, the company acquired Previse to complement the TissueCypher test and expand its position in the gastrointestinal market. The company may face further competition in the future.